Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05235269 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
A Phase 2 study, sponsored by Attralus.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT05235269 is a Phase 2 study that has completed, run by Attralus. The registered enrollment target is 33 participants.
The verdict
NCT05235269, a Phase 2 study, has completed, sponsored by Attralus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis.
Interventions
- DRUG 124I-AT-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05235269
The ClinicalTrials.gov registry entry for NCT05235269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Attralus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 124I-AT-01 is the first listed.
NCT05235269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05235269 about?
NCT05235269 is a clinical study titled "A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis". This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis.
What is the current status of trial NCT05235269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2021-11-30. Estimated completion is 2023-02-24.
What interventions are being tested in trial NCT05235269?
The interventions under investigation include: 124I-AT-01 (DRUG).
Who is sponsoring clinical trial NCT05235269?
This trial is sponsored by Attralus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.